MX2018001074A - Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad. - Google Patents

Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.

Info

Publication number
MX2018001074A
MX2018001074A MX2018001074A MX2018001074A MX2018001074A MX 2018001074 A MX2018001074 A MX 2018001074A MX 2018001074 A MX2018001074 A MX 2018001074A MX 2018001074 A MX2018001074 A MX 2018001074A MX 2018001074 A MX2018001074 A MX 2018001074A
Authority
MX
Mexico
Prior art keywords
natural killer
cell lines
cells
modified
increased cytotoxicity
Prior art date
Application number
MX2018001074A
Other languages
English (en)
Inventor
Eamon Peter O''dwyer Michael
Original Assignee
Onkimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603655.0A external-priority patent/GB201603655D0/en
Priority claimed from GBGB1610164.4A external-priority patent/GB201610164D0/en
Application filed by Onkimmune Ltd filed Critical Onkimmune Ltd
Publication of MX2018001074A publication Critical patent/MX2018001074A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las células NK y las líneas de células NK se modifican para aumentar la citotoxicidad, en donde las células y las composiciones de estas tienen un uso en el tratamiento del cáncer. La producción de células NK y líneas de células NK modificadas es a través de una modificación genética para eliminar la expresión de un receptor inhibidor de puntos de control y/o añadir la expresión del ligando TRAIL mutante (variante).
MX2018001074A 2015-07-29 2016-07-28 Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad. MX2018001074A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15178899 2015-07-29
GBGB1603655.0A GB201603655D0 (en) 2016-03-02 2016-03-02 Modified natural killer cells and natural killer cell lines having increased cytotoxicity
GB201605457 2016-03-31
GBGB1610164.4A GB201610164D0 (en) 2016-06-10 2016-06-10 Modified natural killer cells and natural killer cell lines having increased cytoxicity
PCT/EP2016/068001 WO2017017184A1 (en) 2015-07-29 2016-07-28 Modified natural killer cells and natural killer cell lines having increased cytotoxicity

Publications (1)

Publication Number Publication Date
MX2018001074A true MX2018001074A (es) 2018-11-12

Family

ID=56683913

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001074A MX2018001074A (es) 2015-07-29 2016-07-28 Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.
MX2020010014A MX2020010014A (es) 2015-07-29 2018-01-24 Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010014A MX2020010014A (es) 2015-07-29 2018-01-24 Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.

Country Status (13)

Country Link
US (3) US10034925B2 (es)
EP (6) EP3971284B1 (es)
JP (3) JP6974681B2 (es)
KR (1) KR20180028530A (es)
CN (3) CN116064400A (es)
AU (2) AU2016300128B2 (es)
BR (1) BR112018001660A2 (es)
CA (2) CA3156128A1 (es)
DK (3) DK3317401T3 (es)
ES (5) ES2970269T3 (es)
HK (1) HK1252582B (es)
MX (2) MX2018001074A (es)
WO (1) WO2017017184A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
ES2970269T3 (es) 2015-07-29 2024-05-27 Onk Therapeutics Ltd Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3581190B1 (en) 2016-12-09 2021-03-10 ONK Therapeutics Limited Engineered natural killer cells and uses thereof
CN110168078B (zh) * 2017-01-06 2024-05-14 免疫生物公司 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
DE102017002645A1 (de) * 2017-03-17 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Bestrahlung von Säugetierzellen mit Elektronenstrahlen und/oder Röntgenstrahlen
US11903968B2 (en) 2017-07-21 2024-02-20 Cellectis Engineered immune cells resistant to tumor microenvironment
WO2019016360A1 (en) * 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
JP2021503954A (ja) * 2017-11-24 2021-02-15 オーエヌケイ セラピューティクス リミテッド 腫瘍細胞を標的とする改変されたナチュラルキラー細胞およびナチュラルキラー細胞株
EP3796924A4 (en) * 2018-05-16 2022-01-12 Research Institute at Nationwide Children's Hospital PRODUCTION OF INACTIVATED PRIMARY AND EXTENDED HUMAN NK CELLS USING CAS9 RIBONUCLEOPROTEINS
EP3802795A4 (en) * 2018-06-06 2022-03-16 Stemcell Technologies Canada Inc. KITS, COMPOSITIONS AND METHODS FOR ENRICHMENT OF SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS
CN108743595B (zh) * 2018-06-08 2020-11-27 厦门诺康得生物科技有限公司 一种nk细胞免疫检查点抑制剂及其制备方法
SG11202108644UA (en) * 2019-02-15 2021-09-29 Editas Medicine Inc Modified natural killer (nk) cells for immunotherapy
CN109908155A (zh) * 2019-03-11 2019-06-21 上海中医药大学 丹参酮ⅱa的药物用途
KR102292657B1 (ko) 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
JP2022526504A (ja) * 2019-03-21 2022-05-25 オーエヌケー セラピューティクス リミテッド 細胞死に対する耐性が増大した改変免疫エフェクター細胞
RU2731293C1 (ru) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
EP3789485A1 (en) * 2019-09-06 2021-03-10 ONK Therapeutics Limited Cellular therapies for cancer
CA3153197A1 (en) 2019-10-03 2021-04-08 Ryan T. Gill Crispr systems with engineered dual guide nucleic acids
CN111849896B (zh) * 2020-07-31 2022-07-01 广东昭泰体内生物医药科技有限公司 一种car-nk细胞培养基及其应用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
WO2022263682A1 (en) 2021-06-18 2022-12-22 Onk Therapeutics Limited Double knockout natural killer cells
CA3223311A1 (en) 2021-06-18 2022-12-22 Andrea BARGHETTI Compositions and methods for targeting, editing or modifying human genes
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
CN114796483B (zh) * 2022-06-28 2022-11-08 北京大学 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024100203A1 (en) 2022-11-10 2024-05-16 Onk Therapeutics Limited Combined therapies using immunomodulating drugs
CN116590237B (zh) * 2023-05-29 2023-10-31 上海贝斯昂科生物科技有限公司 一种遗传修饰的自然杀伤细胞及其制备和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004524806A (ja) 2000-06-30 2004-08-19 ユニバーシティ オブ ルイビル リサーチ ファウンデーション，インコーポレイティド 新しい機能のための細胞膜の変更
CA2388441A1 (en) 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
EP1781777A1 (en) * 2004-07-02 2007-05-09 Avaris AB Method for the genetic activation of cells and uses of said cells
CA3052445C (en) * 2004-07-10 2023-08-22 Kerry S. Campbell Genetically modified human natural killer cell lines
EP1621550A1 (en) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
CA2804914A1 (en) 2010-07-22 2012-01-26 Nadir Askenasy Regulatory immune cells with enhanced targeted cell death effect
US9597357B2 (en) * 2012-10-10 2017-03-21 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
CA2902940A1 (en) * 2013-02-27 2014-09-04 The Broad Institute, Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US9816581B2 (en) 2013-07-25 2017-11-14 Bridgestone Corporation Vibration prevention device
ES2741308T3 (es) * 2013-10-15 2020-02-10 Scripps Research Inst Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
ES2939760T3 (es) * 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
CN107075482B (zh) 2014-04-07 2021-03-16 诺华股份有限公司 使用抗cd19嵌合抗原受体治疗癌症
SG10201912171PA (en) 2014-04-18 2020-02-27 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3967709A1 (en) * 2014-09-17 2022-03-16 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN115537396A (zh) 2015-03-27 2022-12-30 哈佛学院校长同事会 经过修饰的t细胞及其制备和使用方法
EP3317399B1 (en) * 2015-06-30 2024-06-26 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
ES2970269T3 (es) * 2015-07-29 2024-05-27 Onk Therapeutics Ltd Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada

Also Published As

Publication number Publication date
EP3317401A1 (en) 2018-05-09
BR112018001660A2 (pt) 2018-09-18
DK3434762T3 (da) 2021-06-07
DK3421590T3 (da) 2021-10-04
EP3421590A1 (en) 2019-01-02
US10960064B2 (en) 2021-03-30
HK1252582A1 (zh) 2019-05-31
ES2876938T3 (es) 2021-11-15
EP3828266B1 (en) 2022-11-23
ES2890859T3 (es) 2022-01-24
ES2701338T3 (es) 2019-02-21
AU2022203339A1 (en) 2022-06-09
KR20180028530A (ko) 2018-03-16
CN108026512B (zh) 2022-09-16
JP2021169473A (ja) 2021-10-28
US20210138051A1 (en) 2021-05-13
EP3421590B1 (en) 2021-07-14
MX2020010014A (es) 2020-10-14
AU2016300128B2 (en) 2022-03-17
EP3434762B1 (en) 2021-03-17
JP2018522592A (ja) 2018-08-16
US20180326029A1 (en) 2018-11-15
CN116064400A (zh) 2023-05-05
RU2018104871A (ru) 2019-08-28
JP7359346B2 (ja) 2023-10-11
ES2939084T3 (es) 2023-04-18
EP3434762A1 (en) 2019-01-30
ES2970269T3 (es) 2024-05-27
CA3156128A1 (en) 2017-02-02
WO2017017184A1 (en) 2017-02-02
CA2993796C (en) 2024-02-20
US20170157230A1 (en) 2017-06-08
CN116064401A (zh) 2023-05-05
RU2018104871A3 (es) 2020-08-17
EP3317401B1 (en) 2018-10-03
US10034925B2 (en) 2018-07-31
AU2016300128A1 (en) 2018-02-22
DK3317401T3 (da) 2019-01-02
EP3878951A1 (en) 2021-09-15
EP3828266A1 (en) 2021-06-02
JP2021178824A (ja) 2021-11-18
CA2993796A1 (en) 2017-02-02
EP3971284B1 (en) 2023-11-08
HK1252582B (zh) 2020-02-07
EP3971284A1 (en) 2022-03-23
JP6974681B2 (ja) 2021-12-01
CN108026512A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
MX2020010014A (es) Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
PH12017501757A1 (en) A novel paenibacillus strain, antifungal compounds, and methods for their use
MX2018010924A (es) Células efectoras inmunitarias con edición genómica.
MX2018015656A (es) Compuestos heterociclicos como antibacterianos.
MX2017002271A (es) Composiciones y metodos para el tratamiento de trastornos neurologicos.
MY191210A (en) Novel promoter and uses thereof
AU366476S (en) Bottle
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
MX359664B (es) Tratamiento de cáncer de mama.
EP3598980A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PH12018500379A1 (en) Biopharmaceutical compositions
MX2017008414A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
NZ731398A (en) Noscapinoid-producing microbes and methods of making and using the same
WO2015106043A3 (en) Novel synthetic biology-based adcc technology
MX2019000677A (es) Células miméticas de células b.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2022005790A (es) Elementos reguladores de planta y metodos para usarlos.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2016011416A (es) Composiciones de glicoproteinas sialiladas y usos de estas.
MX2018011512A (es) Uso de insulina para promover el vaciamiento gástrico.